de Assis, Rafael R.
Jain, Aarti
Nakajima, Rie
Jasinskas, Algis
Felgner, Jiin
Obiero, Joshua M. http://orcid.org/0000-0001-9741-512X
Norris, Philip J.
Stone, Mars
Simmons, Graham
Bagri, Anil
Irsch, Johannes
Schreiber, Martin
Buser, Andreas http://orcid.org/0000-0002-7942-6746
Holbro, Andreas
Battegay, Manuel
Hosimer, Philip
Noesen, Charles
Adenaiye, Oluwasanmi
Tai, Sheldon
Hong, Filbert
Milton, Donald K. http://orcid.org/0000-0002-0550-7834
Davies, D. Huw
Contestable, Paul
Corash, Laurence M.
Busch, Michael P. http://orcid.org/0000-0002-1446-125X
Felgner, Philip L. http://orcid.org/0000-0002-4117-8505
Khan, Saahir http://orcid.org/0000-0001-6732-768X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (KL2 TR001416)
United States Department of Defense | Defense Advanced Research Projects Agency (N66001-17-2-4023, N66001-18-2-4015)
U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (N66001-18-2-4015)
Article History
Received: 3 May 2020
Accepted: 10 November 2020
First Online: 4 January 2021
Competing interests
: The coronavirus antigen microarray is the intellectual property of the Regents of the University of California that is licensed for commercialization to Nanommune Inc. (Irvine, CA), a private company for which P. Felgner is the largest shareholder and several co-authors (R. de Assis, A. Jain, R. Nakajima, A. Jasinskas, J. Obiero, Jiin Felgner, H. Davies, and S. Khan) also own shares. Nanommune Inc. has a business partnership with Sino Biological Inc. (Beijing, China) which expressed and purified the antigens used in this study. The convalescent plasma used in this study was collected for clinical use by independent blood centers using licensed plasma or platelet processing systems manufactured by Cerus Corporation, for which multiple authors (L. Corash, A. Bagri, and Johannes Irsch) are shareholders and employees. Convalescent sera were also provided by Ortho Clinical Diagnostics, which is using these specimens to validate a clinical diagnostic test, and P. Hosimer, C. Noesen, and P. Contestable are shareholders and employees of this company. M. Battegay, A. Buser, A. Holbro, Philip J. Norris, Mars Stone, Graham Simmons, Martin Schreiber, Oluwasanmi Adenaiye, Sheldon Tai, Filbert Hong, Donald K. Milton, Michael P. Busch, and the Prometheus-UMD consortium investigators have no conflicts of interest to disclose.